AstraZeneca advances scientific leadership in haematology at ASH 2023
Calquence six-year follow-up data reinforce long-term benefit in chronic lymphocytic leukaemia, and data across multiple haematology assets showcase breadth of promising early pipeline. New, longer-term data from ALPHA Phase III trial will further show potential of danicopan to address clinically significant extravascular haemolysis and maintain disease control, allowing paroxysmal nocturnal haemoglobinuria patients to continue standard-of-care treatment with Ultomiris or Soliris. AstraZeneca will present new clinical and real-world data in multiple haematological conditions at the 65th
